Patents

CoLucid owns or has exclusive rights to a significant patent portfolio related to the manufacture, sale and use of lasmiditan.

Exclusivity in the US into 2030 is anticipated, based on:

  • Composition of matter patent protection with patent term adjustment – GRANTED
  • Intention to apply for Hatch-Waxman Act patent extension

Additional patent filings for our manufacturing process and dosing regimens, if issued, will provide further protection and extend exclusivity in major markets of the world.

5‑HT1F Receptor Agonists
U.S. Patent No. 7,423,050 "Pyridinoylpiperidines as 5‑HT1F Agonists" Download
US Patent No. 8,044,207 "Pyridinoylpiperidines as 5‑HT1F Agonists" Download
US Patent No. 8,697,876 "Methods of Synthesis of Pyridinoylpiperidine 5‑HT1F Agonists" Download
US Patent No. 8,748,459 "Methods of Synthesis of Pyridinoylpiperidine 5‑HT1F Agonists" Download
WO 2010/115125 "Composition of 2,4,6-Trifluoro-N-[6-(-1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide" Download
Lasmiditan

Lasmiditan

Lasmiditan has a unique pyridinoyl-piperidine chemical scaffold and is completely different from triptans, which act peripherally by constricting blood vessels and are not designed to penetrate the CNS.

Learn More

MIGRAINE QUICK FACTS

Click here for more information on migraine.

Learn More